iGenetic Diagnostics and Lucence Diagnostics partner to deliver cancer blood tests in India.
Lucence Diagnostics, a genomic medicine company focused on personalising cancer care, and iGenetic Diagnostics, a pathology company with operations across India, announced a partnership to distribute Lucence’s liquid biopsy tests for early cancer detection and treatment in India.
iGenetic will be distributing Lucence’s flagship liquid biopsy test LiquidHALLMARK,the world’s first blood test to span multiple cancer-causing mutations and viruses.
This test improves cancer diagnosis and treatment selection for patients with advanced cancer. The blood test analyses the cancer-driving mutations from the DNA shed by the tumour into the bloodstream to determine the best available treatment, which include targeted therapy and immunotherapy.
“We are focused on reducing avoidable cancer deaths, particularly in Asia, where more than four million cancer deaths occur annually”, said Dr. Min-Han Tan, founder and CEO of Lucence Diagnostics.
LiquidHALLMARK targets a wide range of cancers, especially cancer types that are most prevalent in Asia, like lung, colon and breast cancers. The turnaround time for this test is also shorter with results coming back in days instead of over a week for current approaches. The test is based on Lucence’s proprietary molecular watermarking technology AmpliMARK with sensitivity and specificity of up to 99.9 percent, which is supported by its AI-powered clinical analytics engine SunTzu.AI. [APBN]